Drugs / Besifovir
Besifovir
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04249908 | Feb → Sep 2020 | impaired renal function disease | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02792088 | Jul 2015 → Feb 2020 | chronic hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01937806 | Oct 2013 → Feb 2016 | chronic hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04202536 | May 2019 → Jun 2021 | chronic hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Besifovir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02792088 ↗ |
| Known as | Besifovir Dipivoxil Maleate | “Besifovir dipivoxil maleate (BSV) is a new promising treatment for CHB.” PMID 32355123 ↗ Aug 20201“Drug: Besifovir Dipivoxil Maleate” NCT04249908 ↗ |
| Known as | BSV | “Besifovir dipivoxil maleate (BSV) is a new promising treatment for CHB.” PMID 32355123 ↗ Aug 2020 |
| Known as | Lb80331 | ChEMBL registry synonym — accepted as the source's own label CHEMBL329091 ↗ |
| Modality | Other / unclassified | “an acyclic nucleotide phosphonate” PMID 33493393 ↗ Jan 2021 |
| Route | Oral | “Subjects are orally administered with a clinical trial drug q.ds.i.d. for 48 weeks” NCT01937806 ↗ |